|
Synonyms: Compound 1 [WO2025147497] | compound 7 [PMID: 28011205]
Compound class:
Synthetic organic
Comment: Nuvrumetinib is the INN for a mitogen-activated protein kinase (MEK) 1/2 inhibitor, with antineoplastic potential [2]. Structurally it is a macrocyclic molecule. It acts as an allosteric inhibitor, that is one of the compounds claimed in Pasithea Therapeutics' patent WO2025147497A1 [1]. Nuvrumetinib is likely the INN for their lead inhibitor PAS-004.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Nuvrumetinib (PAS-004) was progressed as a clinical anti-tumour agent, in particular for solid tumours with RAS, RAF or NF1 mutations. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | Phase 1 Interventional | Pasithea Therapeutics Corp. | ||
| NCT06299839 | PAS-004 in Patients With Advanced Solid Tumors | Phase 1 Interventional | Pasithea Therapeutics Corp. | ||